Anti-PlGF for the Treatment of Diabetic Macular Edema

Anat Loewenstein, MD

Show Description +

Anat Loewenstein, MD, speaks about the results of the two-stage phase 1/2 trial looking at the safety and efficacy of THR-317, a novel anti-PlGF therapy for the treatment of DME.

Posted: 6/13/2019

Up Next

Name: Anti-PlGF for the Treatment of Diabetic Macular Edema
Uploaded: 2019-06-13T15:15:00+00:00
Description: Anat Loewenstein, MD, speaks about the results of the two-stage phase 1/2 trial looking at the safety and efficacy of THR-317, a novel anti-PlGF therapy for the treatment of DME.

Treat-and-Extend for Neovascular Age-Related Macular Degeneration

Francesco Boscia, MD

The Future of Cell-Derived Therapies for Retinal Disease

Susanne Binder, MD

Technological Advances and Improved Outcomes in Complicated Retinal Detachments Associated With Diabetic Retinopathy

María Berrocal, MD

Comparative Analysis of Retinal Reattachment Surgery With or Without ILM Peeling to Prevent Post-Op Macular Pucker

Matteo Forlini, MD

Back to All Videos

Anti-PlGF for the Treatment of Diabetic Macular Edema

Anat Loewenstein, MD

Anat Loewenstein, MD, speaks about the results of the two-stage phase 1/2 trial looking at the safety and efficacy of THR-317, a novel anti-PlGF therapy for the treatment of DME.

Posted: 6/13/2019

Please log in to leave a comment.

Meeting Coverage:

FLORetina

Anti-PlGF for the Treatment of Diabetic Macular Edema

Up Next

Anti-PlGF for the Treatment of Diabetic Macular Edema

More From FLORetina: 2019 Coverage